← Leaderboards
Edmund L Ellsworth
Michigan State University
$2,242,709
Attributed
$4,485,418
Total exposure
2
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3M · FY2023–25$5M$3.8M$2.5M$1.3M$0
'23
'24
'25
Funding mix
By agency
NIH$4,485,418 · 2
By mechanism
R01$4,485,418 · 2
Top collaborators
- Robert B Abramovitch4 shared
Most similar at Michigan State University
Same institution · by research overlap
- James J Pestka$10,650,154
- Andrew Olive$4,767,603
Others in their field
Other Rising Stars on “Inhibitor”
- Supriya Menezes · The Emmes Company, Llc$25,277,032
- Michael Difilippantonio · Leidos Biomedical Research, Inc.$22,364,766
- Xuping Xie · University Of Texas Med Br Galveston$13,737,799
- Michael George Natchus · Emory University$10,548,554
- John Alam · Eip Pharma, Inc.$10,411,018
- Kenneth Schultz · Trethera Corporation$8,384,949
Research focus
InhibitorMissionEvolutionInfectionMacrophageMicrosomesCytotoxicityCystic FibrosisDesignGlobal HealthEfficacy StudyIn VivoDrug KineticsDrug ResistanceCellsAnalogCessation Of LifeAmericanAntibioticsChronic Obstructive Pulmonary DiseaseDisease TransmissionGenus MycobacteriumBiological AvailabilityMouse Model
Grant awards (4)
New potent orally bioavailable nitro-containing compounds to treat mycobacterial infections$2,248,740
R01 · FY2025 · AI
Chemical biology studies of MmpL3 inhibition and resistance in mycobacteria$729,894
R01 · FY2025 · AI
Chemical biology studies of MmpL3 inhibition and resistance in mycobacteria$747,825
R01 · FY2024 · AI
Chemical biology studies of MmpL3 inhibition and resistance in mycobacteria$758,959
R01 · FY2023 · AI